Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. - Wikidata - wikimedia - TriplyDB

Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator.

Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator.

http://www.wikidata.org/entity/Q44103914

about

A critical role for eukaryotic elongation factor 1A-1 in lipotoxic cell death PPARs and the cardiovascular system Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties Mitochondrial dysfunction in diabetic cardiomyopathy Comprehensive metabolic modeling of multiple 13C-isotopomer data sets to study metabolism in perfused working hearts.Metabolic Remodeling in Diabetic Cardiomyopathy.Lipotoxicity in the heart.Diabetic cardiomyopathy, causes and effects.Cardiac remodeling in obesity.Speckle tracking echocardiography in the diagnosis of early left ventricular systolic dysfunction in type II diabetic mice.Obesity preserves myocardial function during blockade of the glycolytic pathway PPAR-alpha effects on the heart and other vascular tissues.Targeting metabolic disturbance in the diabetic heart.K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome.The PPARalpha-PGC-1alpha Axis Controls Cardiac Energy Metabolism in Healthy and Diseased Myocardium.Individuals with Metabolically Healthy Overweight/Obesity Have Higher Fat Utilization than Metabolically Unhealthy Individuals.PPAR ligands: are they potential agents for cardiovascular disorders?Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases PPARs and the kidney in metabolic syndrome.Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model--the Zucker diabetic rat.REVIEW paper: pathophysiology of myocardial reperfusion injury: the role of genetically engineered mouse models.Reactive oxygen species and insulin-resistant cardiomyopathy.Metabolic therapy at the crossroad: how to optimize myocardial substrate utilization?Protective role of antioxidants in diabetes-induced cardiac dysfunction.Risk factors preceding type 2 diabetes and cardiomyopathy.Preventive and prophylactic mechanisms of action of pomegranate bioactive constituents.Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy.Short-term caloric restriction in db/db mice improves myocardial function and increases high molecular weight (HMW) adiponectin.Endothelial cell-cardiomyocyte crosstalk in diabetic cardiomyopathy.Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids.CYP450, COX-2 and Obesity Related Renal Damage.Effects of Short-term Renovascular Hypertension and Type 2 Diabetes on Cardiac Functions in Rats.Exercise ameliorates chronic kidney disease-induced defects in muscle protein metabolism and progenitor cell function.Role of FoxO1 in FFA-induced oxidative stress in adipocytes.Impaired cardiac functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not structural, remodelling.Chylomicron and palmitate metabolism by perfused hearts from diabetic mice.Control of cardiac pyruvate dehydrogenase activity in peroxisome proliferator-activated receptor-alpha transgenic mice.Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function.Profiling substrate fluxes in the isolated working mouse heart using 13C-labeled substrates: focusing on the origin and fate of pyruvate and citrate carbons.Longitudinal evaluation of myocardial glucose metabolism and contractile function in obese type 2 diabetic db/db mice using small-animal dynamic 18F-FDG PET and echocardiography.

P2860

Q24540224-D5982EED-8889-4B66-8197-EE5080681236 Q24642728-1166F88D-E059-4704-98C2-2E3A692DC171 Q28261771-D168E5C6-FDAF-4623-A10D-2DB9D5F481D2 Q28390863-D767E469-4304-4E5D-AEF4-B889B3C3A7B6 Q31119881-EC888353-25BE-462D-ADDF-1E55A8C6CB03 Q33623469-B38D6A38-75CC-4905-8726-1D434B4FDCD6 Q33665107-CC6CDC32-0C31-4882-884C-D9DE966F2556 Q34038623-4299D2B1-1831-431B-8B07-445C522BB8CF Q34043589-C55A5046-EC2C-4B6B-8948-4C4641D4DBE9 Q34340227-80D5569A-D297-4D36-B850-8F2F1064A3C1 Q34387864-F8F2B95C-B9B4-4486-B8C4-62F86D02D67D Q35080447-154CB3EB-5336-44EE-A1FF-F6E69DD65CBF Q35084845-75B0975C-DDC4-4860-878A-23A9DB0F28ED Q35876408-C165DD21-84A8-47C9-AC0E-63E6538A79DB Q36426768-7DC1F266-6B61-45CB-886C-D439ED57BAA8 Q36507377-FAE472DF-7859-42EE-994B-D4B4049AD79E Q36819094-0A94405F-B8B3-4F17-97E6-A79EE1D56E4D Q36918509-5C377976-22C7-43F7-A672-6A5B9CBF108B Q37072216-37DCCC5F-7B79-435F-972E-1746D33EC189 Q37148890-F1F6AD19-CE09-47EA-8465-CBD556AD5FCE Q37251495-186111D4-E101-42B7-830F-28475AFEACBD Q37577957-4A69680F-8C5B-42C7-B368-B9E4E9AC9AB4 Q37704721-C1F7D945-F6D4-407D-9EF0-EBBA54DE48AC Q37748612-5AE0E870-1458-474F-8735-FD8C36C697B6 Q37769156-0E174723-2075-49F5-A1A7-8B9CF29E2A20 Q38112115-A31F7154-97A4-4093-BED6-D2C72C322974 Q38546383-478965CB-2702-459E-B000-06D8BCB95628 Q38784207-12D33856-75AD-411D-B82A-A855D0880FA5 Q38861823-FFDB1308-BD09-4100-94BC-28383EF991AD Q40425308-A31B62BE-6FCB-4B36-8C94-5AA3BEC869D3 Q40457824-BF05A11E-1B08-41F0-B14F-8646302D142F Q41879374-7FF33564-5521-4557-B5BA-91BC7710EB40 Q42206915-BF28B16B-B70D-4E55-85D1-D02A2582C9B1 Q42829984-05616687-B4D3-4615-8780-422ADC670255 Q43154086-7BCADFA6-7A04-40A6-8CCF-7D8AF22AA826 Q44191957-659FB35C-2B8C-497B-B3C8-B2C8254EBC50 Q44381078-D54904DF-BE54-46FA-86BE-D481B3978F4E Q44643868-1C62796C-FE5D-44AC-B4DB-B76B6A19ECC5 Q44689992-44F8F7E0-A823-4B73-91CC-5818A3F556C3 Q45383809-C927C000-F89A-4CDB-AD6A-45029C9AECC7

P2860

Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator.

http://www.wikidata.org/entity/Q44103914

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Cardiac function and metabolis ...... a novel PPAR-alpha activator.

@en

Cardiac function and metabolis ...... a novel PPAR-alpha activator.

@nl

type

label

Cardiac function and metabolis ...... a novel PPAR-alpha activator.

@en

Cardiac function and metabolis ...... a novel PPAR-alpha activator.

@nl

prefLabel

Cardiac function and metabolis ...... a novel PPAR-alpha activator.

@en

Cardiac function and metabolis ...... a novel PPAR-alpha activator.

@nl

P1433

Q44103914-096DCFDC-4FF4-473A-9E2C-49AAF3CB0394

P1476

Q44103914-93986D0B-378B-45EF-9348-4C142CA17907

P2093

Q44103914-12DBCCB0-01BC-4B03-9E51-BDF715774593

Q44103914-2DD30179-83BB-4A1D-9804-1CC0EB796B91

Q44103914-5295A917-2CF6-4628-853C-C9173A3088A1

Q44103914-5CF93A49-4EB5-4E6E-8313-30C89418D459

Q44103914-9CCB30B8-3223-403C-B015-6935B4543641

Q44103914-EBE5552B-A63C-4655-831C-60C9630314EE

Q44103914-FAB58AD3-7388-4250-99A8-F52E93CF7222

P2860

Q44103914-02A06ACE-DDB0-49C2-BA88-EAFA1BC9CA84

Q44103914-1F49C425-6E54-4439-A8AE-D75E3EBACC23

Q44103914-2128ACFD-4BA4-4CFF-8725-BC1D41D4DD80

Q44103914-2A07722B-EB2E-4F35-BE33-F8D230939978

Q44103914-35057E97-3CF9-41DC-AB5B-BCA5758F2C02

Q44103914-3CEAF110-6201-41DB-88BD-70D090959E3E

Q44103914-44BFFA0D-292A-464F-9607-53D520C7B31E

Q44103914-4BB4D081-A79C-49F8-AE9A-78E1A95ABC16

Q44103914-500448BD-7218-4885-AE7D-0976CFF573F9

Q44103914-53CD813A-0B33-4B3A-8623-9A3D3F6C110E

P304

Q44103914-97EF1C63-E94B-4258-9240-DCB7EA743C15

P31

Q44103914-DC5401AD-031D-42BC-BED8-A3991F61357A

P356

Q44103914-914409BE-6800-4137-B8E0-42B9065FA019

P433

Q44103914-93116270-7D5D-4FCF-82FB-992D190CA97A

P478

Q44103914-DB4C7B32-43A8-4D51-9538-F85C8C6674BA

P577

Q44103914-4ED2F7FE-BA75-49B8-9C7B-AF82AFB78D21

P5875

Q44103914-438DFA7A-12B7-4F33-9558-70DE1DE9DA37

P698

Q44103914-494CF564-E887-45DC-8AE4-4CCD5A361D81

P356

AJPHEART.00226.2001

P1433

American Journal of Physiology - Heart and Circulatory Physiology

P1476

Cardiac function and metabolis ...... a novel PPAR-alpha activator.

@en

P2093

Darrell D Belke

http://www.w3.org/2001/XMLSchema#string

David L Severson

http://www.w3.org/2001/XMLSchema#string

Ellen Aasum

http://www.w3.org/2001/XMLSchema#string

Marie Cooper

http://www.w3.org/2001/XMLSchema#string

Morten Andreassen

http://www.w3.org/2001/XMLSchema#string

Rudolph A Riemersma

http://www.w3.org/2001/XMLSchema#string

Terje S Larsen

http://www.w3.org/2001/XMLSchema#string

P2860

The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus

Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis.

Roles of PPARs in health and disease.

Insulin resistance and cardiovascular disease.

Free fatty acids and pathogenesis of type 2 diabetes mellitus.

Cardiovascular disease in diabetes mellitus type 2: a potential role for novel cardiovascular risk factors.

PPAR signaling in the control of cardiac energy metabolism.

Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice.

Developmental changes in energy substrate use by the heart.

P304

H949-57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPHEART.00226.2001

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

283

http://www.w3.org/2001/XMLSchema#string

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11206499

http://www.w3.org/2001/XMLSchema#string

P698

12181123

http://www.w3.org/2001/XMLSchema#string